Cargando…

Concordance of Treatment Recommendations for Metastatic Non-Small-Cell Lung Cancer Between Watson for Oncology System and Medical Team

OBJECTIVE: The disease complexity of metastatic non-small-cell lung cancer (mNSCLC) makes it difficult for physicians to make clinical decisions efficiently and accurately. The Watson for Oncology (WFO) system of artificial intelligence might help physicians by providing fast and precise treatment r...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Hai-Sheng, Gao, Chun-Xia, Wang, Hai-Bin, Luo, Sai-Sai, Chen, Si-Ying, Dong, Ya-Lin, Lyu, Jun, Tian, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083631/
https://www.ncbi.nlm.nih.gov/pubmed/32214852
http://dx.doi.org/10.2147/CMAR.S244932
_version_ 1783508563587497984
author You, Hai-Sheng
Gao, Chun-Xia
Wang, Hai-Bin
Luo, Sai-Sai
Chen, Si-Ying
Dong, Ya-Lin
Lyu, Jun
Tian, Tao
author_facet You, Hai-Sheng
Gao, Chun-Xia
Wang, Hai-Bin
Luo, Sai-Sai
Chen, Si-Ying
Dong, Ya-Lin
Lyu, Jun
Tian, Tao
author_sort You, Hai-Sheng
collection PubMed
description OBJECTIVE: The disease complexity of metastatic non-small-cell lung cancer (mNSCLC) makes it difficult for physicians to make clinical decisions efficiently and accurately. The Watson for Oncology (WFO) system of artificial intelligence might help physicians by providing fast and precise treatment regimens. This study measured the concordance of the medical treatment regimens of the WFO system and actual clinical regimens, with the aim of determining the suitability of WFO recommendations for Chinese patients with mNSCLC. METHODS: Retrospective data of mNSCLC patients were input to the WFO, which generated a treatment regimen (WFO regimen). The actual regimen was made by physicians in a medical team for patients (medical-team regimen). The factors influencing the consistency of the two treatment options were analyzed by univariate and multivariate analyses. RESULTS: The concordance rate was 85.16% between the WFO and medical-team regimens for mNSCLC patients. Logistic regression showed that the concordance differed significantly for various pathological types and gene mutations in two treatment regimens. Patients with adenocarcinoma had a lower rate of “recommended” regimen than those with squamous cell carcinoma. There was a statistically significant difference in EGFR-mutant patients for “not recommended” regimens with inconsistency rate of 18.75%. In conclusion, the WFO regimen has 85.16% consistency rate with medical-team regimen in our treatment center. The different pathological type and different gene mutation markedly influenced the agreement rate of the two treatment regimens. CONCLUSION: WFO recommendations have high applicability to mNSCLC patients in our hospital. This study demonstrates that the valuable WFO system may assist the doctors better to determine the accurate and effective treatment regimens for mNSCLC patients in the Chinese medical setting.
format Online
Article
Text
id pubmed-7083631
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-70836312020-03-25 Concordance of Treatment Recommendations for Metastatic Non-Small-Cell Lung Cancer Between Watson for Oncology System and Medical Team You, Hai-Sheng Gao, Chun-Xia Wang, Hai-Bin Luo, Sai-Sai Chen, Si-Ying Dong, Ya-Lin Lyu, Jun Tian, Tao Cancer Manag Res Original Research OBJECTIVE: The disease complexity of metastatic non-small-cell lung cancer (mNSCLC) makes it difficult for physicians to make clinical decisions efficiently and accurately. The Watson for Oncology (WFO) system of artificial intelligence might help physicians by providing fast and precise treatment regimens. This study measured the concordance of the medical treatment regimens of the WFO system and actual clinical regimens, with the aim of determining the suitability of WFO recommendations for Chinese patients with mNSCLC. METHODS: Retrospective data of mNSCLC patients were input to the WFO, which generated a treatment regimen (WFO regimen). The actual regimen was made by physicians in a medical team for patients (medical-team regimen). The factors influencing the consistency of the two treatment options were analyzed by univariate and multivariate analyses. RESULTS: The concordance rate was 85.16% between the WFO and medical-team regimens for mNSCLC patients. Logistic regression showed that the concordance differed significantly for various pathological types and gene mutations in two treatment regimens. Patients with adenocarcinoma had a lower rate of “recommended” regimen than those with squamous cell carcinoma. There was a statistically significant difference in EGFR-mutant patients for “not recommended” regimens with inconsistency rate of 18.75%. In conclusion, the WFO regimen has 85.16% consistency rate with medical-team regimen in our treatment center. The different pathological type and different gene mutation markedly influenced the agreement rate of the two treatment regimens. CONCLUSION: WFO recommendations have high applicability to mNSCLC patients in our hospital. This study demonstrates that the valuable WFO system may assist the doctors better to determine the accurate and effective treatment regimens for mNSCLC patients in the Chinese medical setting. Dove 2020-03-16 /pmc/articles/PMC7083631/ /pubmed/32214852 http://dx.doi.org/10.2147/CMAR.S244932 Text en © 2020 You et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
You, Hai-Sheng
Gao, Chun-Xia
Wang, Hai-Bin
Luo, Sai-Sai
Chen, Si-Ying
Dong, Ya-Lin
Lyu, Jun
Tian, Tao
Concordance of Treatment Recommendations for Metastatic Non-Small-Cell Lung Cancer Between Watson for Oncology System and Medical Team
title Concordance of Treatment Recommendations for Metastatic Non-Small-Cell Lung Cancer Between Watson for Oncology System and Medical Team
title_full Concordance of Treatment Recommendations for Metastatic Non-Small-Cell Lung Cancer Between Watson for Oncology System and Medical Team
title_fullStr Concordance of Treatment Recommendations for Metastatic Non-Small-Cell Lung Cancer Between Watson for Oncology System and Medical Team
title_full_unstemmed Concordance of Treatment Recommendations for Metastatic Non-Small-Cell Lung Cancer Between Watson for Oncology System and Medical Team
title_short Concordance of Treatment Recommendations for Metastatic Non-Small-Cell Lung Cancer Between Watson for Oncology System and Medical Team
title_sort concordance of treatment recommendations for metastatic non-small-cell lung cancer between watson for oncology system and medical team
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083631/
https://www.ncbi.nlm.nih.gov/pubmed/32214852
http://dx.doi.org/10.2147/CMAR.S244932
work_keys_str_mv AT youhaisheng concordanceoftreatmentrecommendationsformetastaticnonsmallcelllungcancerbetweenwatsonforoncologysystemandmedicalteam
AT gaochunxia concordanceoftreatmentrecommendationsformetastaticnonsmallcelllungcancerbetweenwatsonforoncologysystemandmedicalteam
AT wanghaibin concordanceoftreatmentrecommendationsformetastaticnonsmallcelllungcancerbetweenwatsonforoncologysystemandmedicalteam
AT luosaisai concordanceoftreatmentrecommendationsformetastaticnonsmallcelllungcancerbetweenwatsonforoncologysystemandmedicalteam
AT chensiying concordanceoftreatmentrecommendationsformetastaticnonsmallcelllungcancerbetweenwatsonforoncologysystemandmedicalteam
AT dongyalin concordanceoftreatmentrecommendationsformetastaticnonsmallcelllungcancerbetweenwatsonforoncologysystemandmedicalteam
AT lyujun concordanceoftreatmentrecommendationsformetastaticnonsmallcelllungcancerbetweenwatsonforoncologysystemandmedicalteam
AT tiantao concordanceoftreatmentrecommendationsformetastaticnonsmallcelllungcancerbetweenwatsonforoncologysystemandmedicalteam